Industry Insights

  1. Why Tolerability Will Drive The Next Wave Of Obesity Treatments 5/29/2026

    For the next generation of obesity medicines, enhancing how patients experience therapy will inform discovery and development efforts and may ultimately determine long-term success.

  2. Why Cell And Gene Therapy Has Not Reached More Patients — And Why Clinical Operations Is The Bridge 5/29/2026
  3. Safety Is The Mantra In Kivu Bioscience's ADC Trials For Solid Tumors 5/29/2026

    Kivu Bioscience CEO Mohit Trikha, Ph.D., contends that safer ADCs enable higher effective dosing and could elicit a better response in solid tumors. In this Q&A, he also discusses how parallel trial execution, global site strategy, and stakeholder collaboration support rapid, data-driven development.

  4. Advantages Of Integrated Clinical Trial Management 5/28/2026

    Disconnected trial systems slow sites and patients. Centralizing logistics, payments, and data improves visibility, reduces admin work, and keeps enrollment on track for more patient‑focused studies.

  5. Pay-By-Procedure Or Pay-By-Visit: Which Model Fits Your Trial? 5/28/2026

    Site payment models shape trial cost and execution. Compare visit‑based simplicity vs procedure‑level precision to see when flexibility and savings beat complexity — or when predictability wins.

     

  6. The New Reality Of Clinical Trial Payment 5/28/2026

    Modern trials need financial workflows that match their complexity — align payments to procedures, centralize spend, and reduce delays to protect cash flow, support patients, and improve execution.

  7. Ethical & Regulatory Considerations For Pediatric Gene Therapy 5/28/2026

    Understanding risk thresholds, consent requirements, and IRB expectations early can prevent redesign, reduce delays, and improve trial feasibility for vulnerable patient populations

  8. Taking On Patient Recruitment From Another Angle — The Payer 5/28/2026

    Medzown CEO Jennifer Carter, MD, discusses the challenge of patient recruitment and how coalescing around clinical care data might be a better “in” for recruitment. 

  9. Early-Stage Biotech's AI Advantage Is A Window That Closes 5/27/2026

    FDA AI guidance won’t build your strategy for you. Learn how biotech teams can avoid retrofits and design smarter clinical AI from day one.

  10. Where PRO Strategy Goes Wrong 5/27/2026

    PRO and COA strategy is now central to trial success. Organizations that capture meaningful patient experience data will gain stronger evidence and a regulatory advantage.